News Search Results
Apr 17, 2025, 20:00 ET 鈦隼生技が第一金証券と提携し、上場支援計画を開始
竹北市、2025年4月18日/PRNewswire/ -- 鈦隼生物科技股份有限公司（Brain Navi Biotechnology Co., Ltd.、以下「ブレインナビ」と略称）は、第一金証券（本社 高雄市）とIPO支援契約を締結し、正式に上場支援計画を開始しました。これにより、資本市場への進出を目指します。
More news about: Brain Navi
Apr 17, 2025, 11:03 ET James Gromann Joins Rubin and Rudman's Real Estate Practice Group
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Apr 17, 2025, 11:00 ET Scion Life Sciences Expands Team with Appointment of Three Venture Partners
April 17, 2025 /PRNewswire/ -- Scion Life Sciences ("Scion"), a venture capital firm dedicated to founding and building exceptional biotechnology companies, today announced the appointment of Lalo Flores, Ph.D., Huw Nash, Ph.D.
More news about: Scion Life Sciences
Apr 17, 2025, 10:00 ET Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board
pharmaceutical company acquired by Sanofi Pasteur, and Transmolecular, Inc., a biotechnology company developing cancer diagnostics and treatments. He has also held senior positions in a number of pharmaceutical and biotechnology companies, including Morphotek and Vicuron Pharmaceuticals, and currently serves
More news about: Monument Therapeutics
Apr 17, 2025, 10:00 ET Lilly confirms date and conference call for first-quarter 2025 financial results announcement
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Apr 17, 2025, 09:00 ET BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call. About BioMarinBioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The
More news about: BioMarin Pharmaceutical Inc.
Apr 17, 2025, 07:30 ET Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
Apr 17, 2025, 07:15 ET Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders
thriving in one of the most challenging biotechnology environments in a generation: Delivered total stockholder returns of 267% over the past five years, far exceeding the performance of the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index3.Achieved
More news about: Dynavax Technologies
Apr 17, 2025, 07:00 ET Eugène Riconneaus introduces ER Ocean Recherche - Redesigning fashion materials in a laboratory
ER Ocean Recherche, a pioneering project at the intersection of material design, biotechnology, and environmental responsibility. Inspired by biomimicry, this initiative transforms one of the ocean's most overlooked resources—marine biomass—into
More news about: ER Ocean Recherche
Apr 17, 2025, 06:45 ET Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Apr 17, 2025, 05:45 ET The Gross Law Firm Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: The Gross Law Firm
Apr 16, 2025, 11:03 ET NEUVOGEN Appoints James P. Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D to its Scientific Advisory Board
April 16, 2025 /PRNewswire/ -- NEUVOGEN, Inc., a San Diego based biotechnology company with a next-generation cancer vaccine platform, announced today the appointments of James P. Allison, Ph.D.,
More news about: NEUVOGEN, Inc.
Apr 16, 2025, 09:00 ET Petauri Unites Mtech Access and Delta Hat Under One Team--Petauri Evidence
Petauri Evidence is dedicated to helping pharmaceutical, biotechnology, and medical device companies generate and apply real-world evidence to inform healthcare decision-making. By integrating Mtech Access's established
More news about: Petauri
Apr 16, 2025, 08:00 ET Nanostics Receives CPSA Accreditation for its Newly Relocated Clinical Laboratory at the Biotechnology Business Development Centre in Edmonton
Nanostics clinical lab relocates to Applied Pharmaceutical Innovation's newly upgraded Biotechnology Business Development Centre in the Edmonton Research Park.Nanostics clinical lab has been granted provisional accreditation from the College of Physicians
More news about: Nanostics
Apr 16, 2025, 07:36 ET Global Health Innovators recognised with Abu Dhabi Global Health Week Innovation Awards for transformative impact
contributions are advancing the future of health. Winners of the ADGHW Innovation Awards 2025 were recognised for pioneering solutions in digital health, biotechnology, and diagnostics, receiving global recognition and a share of the $200,000 prize fund.
More news about: Abu Dhabi Global Health Week (ADGHW)
Apr 16, 2025, 07:25 ET Global Health Innovators recognised with Abu Dhabi Global Health Week Innovation Awards for transformative impact
future of health. Winners of the ADGHW Innovation Awards 2025 were recognised for pioneering solutions in digital health, biotechnology, and diagnostics, receiving global recognition and a share of the $200,000 prize fund.
More news about: Abu Dhabi Global Health Week (ADGHW)
Apr 16, 2025, 07:01 ET Grown Alchemist Launches in US on Nordstrom.com
Grown Alchemist, the beauty brand that engineers plant-powered solutions using cutting edge biotechnology to achieve total skin health, has expanded its footprint in the US, launching with luxury retailer, Nordstrom, on their e-commerce platform.
More news about: Grown Alchemist
Apr 16, 2025, 06:59 ET Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced that the
More news about: Q32 Bio
Apr 16, 2025, 04:00 ET Chime Biologics Partners Polpharma Biologics to Advance Global Biosimilar Development
commercial supply. Meeting Global Supply Needs Polpharma Biologics, a major player in the global biosimilar market and the largest biotechnology company in Poland, brings a robust pipeline that includes multiple early-stage and late-stage biosimilars, along
More news about: Chime Biologics
Apr 15, 2025, 16:05 ET Flamingo Therapeutics Announces Poster Presentation on the Immune-Modulatory Effects of Danvatirsen at the American Association for Cancer Research (AACR) Annual Meeting
undruggable transcription factors and long non-coding RNAs. Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Abrdn (formerly funds managed by Tekla Capital Management LLC), Andera Partners, Bpifrance Large Venture, Bpifrance through
More news about: Flamingo Therapeutics
Apr 15, 2025, 14:44 ET Celebrated Intellectual Property Attorney Malaika Tyson Joins Lathrop GPM's Chicago Office
patent litigation and European Patent Office patent opposition practice. She represents clients in various areas – particularly in the life science, biotechnology, pharmaceutical, chemical and material sciences and consumer goods industries. "I am excited to join the excellent IP attorneys at Lathrop
More news about: Lathrop GPM
Apr 15, 2025, 09:55 ET ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and reminds investors of the May 20, 2025 deadline to seek the
More news about: Faruqi & Faruqi, LLP
Apr 15, 2025, 09:04 ET Wayfinder Biosciences and Daiichi Sankyo collaborate to develop novel RNA-targeting therapies for neurodegenerative disease
SEATTLE, April 15, 2025 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company targeting RNA with small molecules, announced today a collaboration with Daiichi Sankyo focused on a key neurodegeneration target.
More news about: Wayfinder Biosciences, Inc.
Apr 15, 2025, 09:00 ET Evommune Initiates Phase 2b Trial of MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Chronic Spontaneous Urticaria
Calif., April 15, 2025 /PRNewswire/ -- Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment of the first patient
More news about: Evommune, Inc
Apr 15, 2025, 08:35 ET Pilatus Biosciences to Present Research on PLT012 at AACR 2025
metabolic and immunological diseases. About Pilatus Biosciences Pilatus Biosciences, a U.S./Swiss-based preclinical stage biotechnology company founded in 2022 with origins at the Ludwig Institute for Cancer Research (Lausanne). The company develops first-in-class biologics targeting
More news about: Pilatus Biosciences